Monte Rosa Therapeutics (NASDAQ:GLUE) Given New $30.00 Price Target at Guggenheim

Monte Rosa Therapeutics (NASDAQ:GLUE) had its price objective dropped by stock analysts at Guggenheim from $34.00 to $30.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price target indicates a potential upside of 87.15% from the stock’s previous close.

A number of other equities analysts have also recently commented on GLUE. Jefferies Financial Group reissued a “buy” rating and issued a $31.00 price objective on shares of Monte Rosa Therapeutics in a research note on Wednesday, January 7th. Wells Fargo & Company increased their price target on shares of Monte Rosa Therapeutics from $22.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, January 8th. Wedbush reiterated an “outperform” rating and issued a $37.00 price target on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 7th. Piper Sandler reissued an “overweight” rating and set a $37.00 price objective (up from $27.50) on shares of Monte Rosa Therapeutics in a research note on Wednesday, January 14th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Monte Rosa Therapeutics in a research report on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $32.80.

Monte Rosa Therapeutics Stock Performance

NASDAQ GLUE opened at $16.03 on Wednesday. The company has a market capitalization of $1.04 billion, a P/E ratio of 50.10 and a beta of 1.63. Monte Rosa Therapeutics has a one year low of $3.50 and a one year high of $25.77. The stock has a 50 day moving average price of $20.13 and a 200-day moving average price of $14.75.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its quarterly earnings results on Thursday, March 19th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.10). The business had revenue of $2.78 million during the quarter, compared to the consensus estimate of $17.09 million. Monte Rosa Therapeutics had a return on equity of 8.28% and a net margin of 11.54%. As a group, equities analysts predict that Monte Rosa Therapeutics will post -1.49 EPS for the current fiscal year.

Insider Activity

In related news, CEO Markus Warmuth sold 5,466 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $17.92, for a total transaction of $97,950.72. Following the transaction, the chief executive officer directly owned 613,471 shares in the company, valued at approximately $10,993,400.32. This represents a 0.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Edmund Dunn sold 25,164 shares of the stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $18.10, for a total transaction of $455,468.40. Following the completion of the sale, the insider directly owned 22,693 shares in the company, valued at $410,743.30. This trade represents a 52.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 36,771 shares of company stock valued at $693,692 in the last 90 days. Company insiders own 6.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. GAMMA Investing LLC bought a new position in shares of Monte Rosa Therapeutics during the fourth quarter valued at approximately $30,000. Russell Investments Group Ltd. purchased a new stake in shares of Monte Rosa Therapeutics in the third quarter worth approximately $32,000. Lazard Asset Management LLC lifted its stake in shares of Monte Rosa Therapeutics by 42.9% during the 2nd quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock worth $48,000 after acquiring an additional 3,262 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of Monte Rosa Therapeutics by 16.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock worth $49,000 after acquiring an additional 451 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Monte Rosa Therapeutics by 32.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after acquiring an additional 776 shares during the period. Hedge funds and other institutional investors own 79.96% of the company’s stock.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.